Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Life Technologies has signed a non-exclusive agreement with iPS Academia Japan to acquire induced pluripotent stem (iPS) cell patent portfolio rights.
Subscribe to our email newsletter
The licence will help Life Technologies to expand its products and services for the iPS cell research community.
The agreement also allows Life Technologies leverages to sell iPS cells and to develop and commercialize products designed to create iPS cells and differentiate them into any cell type for use in drug discovery and pre-clinical research.
Academia Japan president and CEO Shosaku Murayama said,"We believe that Life Technologies’ business will contribute to boost research and development for practical application of iPS cell technology.”
Life Technologies President and COO Mark Stevenson said,”The agreement positions the company to initiate development and commercialisation of products designed to create iPS cells and differentiate them into any cell type for use in drug discovery and pre-clinical research."